HtrA2 polyclonal, anti-human, mouse, rat, rabbit, bovine, dog

Protein Family: Enzymes, Chaperones and Folding Catalysts, Peptidases

Pathway and Disease: Neurodegenerative Disorders

Description:
Serine protease HTRA2, mitochondrial (HtrA2) is a serine protease that shows proteolytic activity against a non-specific substrate beta-casein. HtrA2 promotes or induces cell death either by direct binding to and inhibition of BIRC proteins (also called inhibitor of apoptosis proteins, IAPs), leading to an increase in caspase activity, or by a BIRC inhibition-independent, caspase-independent and serine protease activity-dependent mechanism. HtrA2 cleaves THAP5 and promotes its degradation during apoptosis. Defects in HtrA2 are the cause of Parkinson disease type 13 (PARK13), a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins) in surviving neurons in various areas of the brain.

Alternate Names: HtrA2, OMI, Serine protease HTRA2, mitochondrial, High temperature requirement protein A2, Omi stress-regulated endoprotease, Serine proteinase OMI, Serine protease 25, HTRA2, PRSS25 

Application Notes: E: 1:500-1:1,000; WB: 1:100-1:500; IHC: 1:100-1:500; IP: 1:100-1:500

Accession No.: O43464

Antigen: KLH-conjugated synthetic peptide encompassing a sequence within the N-term region of human HtrA2.

Format: Each vial contains 0.1 mg IgG in 0.1 ml (1 mg/ml) of PBS pH7.4 with 0.09% sodium azide. Antibody was purified by Protein-G affinity chromatography.

Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.